We are live on
!
Find out more
N
Nuveen Portfolio holdings
AUM
$369B
1-Year Est. Return
31.66%
This Fund
S&P 500
This Quarter
Est. Return
-2.85%
1 Year Est. Return
+31.66%
3 Year Est. Return
+110.02%
5 Year Est. Return
+148.02%
10 Year Est. Return
+492.84%
AUM
$247B
AUM Growth
-$11.7B
(-4.5%)
Cap. Flow
-$1.08B
Cap. Flow
% of AUM
-0.44%
Top 10 Holdings %
Top 10 Hldgs %
21.96%
Holding
3,327
New
107
Increased
1,095
Reduced
1,938
Closed
58
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$3.11B |
| 2 |
iShares Russell 1000 Growth ETF
IWF
|
+$300M |
| 3 |
Baxter International
BAX
|
+$237M |
| 4 |
American Tower
AMT
|
+$196M |
| 5 |
UnitedHealth
UNH
|
+$193M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$343M |
| 2 |
Meta Platforms (Facebook)
META
|
+$300M |
| 3 |
Microsoft
MSFT
|
+$294M |
| 4 |
Salesforce
CRM
|
+$266M |
| 5 |
Match Group
MTCH
|
+$248M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.83% |
| 2 | Healthcare | 15.1% |
| 3 | Financials | 12.26% |
| 4 | Consumer Discretionary | 11.08% |
| 5 | Industrials | 8.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1951
Phibro Animal Health
PAHC
$1.39B
| $4.43M | ﹤0.01% |
333,465
-5,649
| -2% | -$97.5K |
|
1952
Vericel Corp
VCEL
$2.31B
| $4.41M | ﹤0.01% |
190,046
-7,631
| -4% | -$208K |
|
1953
Veracyte
VCYT
$3.8B
| $4.39M | ﹤0.01% |
264,696
-5,245
| -2% | -$118K |
|
1954
St. Joe Company
JOE
$3.83B
| $4.39M | ﹤0.01% |
137,011
-48,040
| -26% | -$1.86M |
|
1955
AAR Corp
AIR
$5.76B
| $4.38M | ﹤0.01% |
122,300
-2,856
| -2% | -$122K |
|
|
PRA
1956
DELISTED
ProAssurance
PRA
| $4.36M | ﹤0.01% |
223,575
-6,395
| -3% | -$140K |
|
1957
Arcus Biosciences
RCUS
$3.64B
| $4.36M | ﹤0.01% |
166,675
-4,956
| -3% | -$131K |
|
1958
Griffon
GFF
$4.86B
| $4.36M | ﹤0.01% |
147,621
-5,768
| -4% | -$175K |
|
1959
Entravision Communication
EVC
$1.1B
| $4.35M | ﹤0.01% |
1,095,820
-22,691
| -2% | -$112K |
|
1960
Clean Energy Fuels
CLNE
$346M
| $4.35M | ﹤0.01% |
814,149
-337,478
| -29% | -$2.11M |
|
1961
Univest Financial
UVSP
$1.18B
| $4.35M | ﹤0.01% |
185,087
-8,348
| -4% | -$211K |
|
1962
First Bancorp
FBNC
$2.68B
| $4.32M | ﹤0.01% |
118,170
-3,321
| -3% | -$122K |
|
1963
Worthington Enterprises
WOR
$2.86B
| $4.32M | ﹤0.01% |
183,716
-5,356
| -3% | -$164K |
|
1964
Cohu
COHU
$2.5B
| $4.31M | ﹤0.01% |
167,298
-21,216
| -11% | -$589K |
|
|
NVEI
1965
DELISTED
Nuvei Corporation Subordinate Voting Shares
NVEI
| $4.31M | ﹤0.01% |
115,481
| – | – |
|
1966
Marten Transport
MRTN
$1.22B
| $4.31M | ﹤0.01% |
224,791
-5,747
| -2% | -$115K |
|
|
NSCS
1967
DELISTED
Nuveen Small Cap Select ETF
NSCS
| $4.3M | ﹤0.01% |
220,000
| – | – |
|
1968
Lyell Immunopharma
LYEL
$360M
| $4.28M | ﹤0.01% |
29,185
-707
| -2% | -$95.7K |
|
1969
SiTime
SITM
$21.8B
| $4.27M | ﹤0.01% |
54,189
-1,444
| -3% | -$186K |
|
1970
State Street SPDR S&P Biotech ETF
XBI
$10.3B
| $4.25M | ﹤0.01% |
+53,629
| New | +$4.52M |
|
1971
Primoris Services
PRIM
$4.45B
| $4.25M | ﹤0.01% |
261,669
-8,527
| -3% | -$178K |
|
1972
Weis Markets
WMK
$1.86B
| $4.24M | ﹤0.01% |
59,517
-1,495
| -2% | -$117K |
|
1973
Aspen Aerogels
ASPN
$518M
| $4.24M | ﹤0.01% |
459,271
-3,855
| -0.8% | -$46.7K |
|
|
CERE
1974
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $4.22M | ﹤0.01% |
149,411
-69,334
| -32% | -$2.06M |
|
1975
LiveRamp
RAMP
$2.3B
| $4.21M | ﹤0.01% |
232,099
-7,039
| -3% | -$163K |
|
Similar funds
VFT
Nuveen's Q3 2022 Portfolio in Review
As of Q3 2022, Nuveen held 3,327 positions worth $247B, down 4.5% from $259B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Trading was light in Q3 2022: portfolio turnover was 5%. Nuveen opened 107 new positions and exited 58, leaving the 3,327-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 24% a quarter earlier, followed by Healthcare and Financials.
- Nuveen's largest Q3 2022 buy was Alibaba: 1,014,906 shares worth $81.2M.
- Nuveen added most to Alnylam Pharmaceuticals in Q3 2022, an estimated $3.11B increase.
- Nuveen's biggest Q3 2022 reduction was Alphabet (Google) Class A, cutting an estimated $343M.
- Nuveen fully exited Atlassian in Q3 2022, selling an estimated $82.9M.
- Nuveen's ten largest holdings make up 22% of its $247B portfolio in Q3 2022.
- Nuveen opened 107 new positions and closed 58 in Q3 2022.
- Nuveen's portfolio value fell 4.5% quarter-over-quarter to $247B.
Based on Nuveen's 13F filing for Q3 2022, filed 14 Nov 2022.